期刊文献+

赖氨酰氧化酶样-4与丝氨酸蛋白酶基因在人宫颈癌细胞中的表达 被引量:1

The Expression of Lysyloxidase-like 4 and Serine Protease Genes in Human Cervical Carcinoma Cell Lines in Human Cancer Cells
下载PDF
导出
摘要 目的探讨赖氨酰氧化酶样-4(LOXL4)和丝氨酸蛋白酶(Matriptase)在三株人宫颈癌细胞中的表达情况。方法采用qRT-PCR及Western blot方法检测三株体外培养的宫颈癌细胞株Hela、ME180、HCC94中赖氨酰氧化酶样-4和Matriptase mRNA的表达及LOXL4蛋白的翻译水平。结果 LOXL4 mRNA在三株人宫颈癌细胞中存在不同程度的表达,蛋白翻译水平与mRNA基因表达一致,以Hela表达为最高,ME180次之,HCC94表达最低;而ME180和HCC94中MatriptasemRNA相对表达丰度分别是Hela的4.09倍和12.40倍。结论本研究成功建立了LOXL4及Matriptase在体外培养宫颈癌细胞中表达的检测平台,LOXL4、Matriptase的相对表达水平可能与宫颈癌细胞的侵袭和迁移能力有关。 Objective To investigate the expression of LOXL4 and Matriptase in three human cervical carcinoma cell lines.Methods LOXL4 and Matriptase mRNA levels were tested by quantitave real-time PCR and LOXL4 protein level was investigated by western-blot in cervical carcinoma cell lines Hela, ME180 and HCC94, respectively. Results Differential expression were found both in LOXL4 gene and protein levels of all the three human cervical carcinoma cell linesin vitro. Hela was the highest expression,followed by ME180 and HCC94 was the lowest.The relative abundances of Matriptase in ME180 and HCC94 were 4.09 and 12.40 times as high as that in Hela. Conclusion This study has successfully established detection platformfor LOXL4 and Matriptase gene expression in cervical carcinoma cells. The expressionsof LOXL4 and Matriptase might be associated with invasion and metastasis of cervical cancer cells.
出处 《中国医药指南》 2014年第10期4-5,7,共3页 Guide of China Medicine
基金 2010年福州市科技计划项目(项目编号:2010-S-88)
关键词 宫颈癌 基因表达 蛋白免疫印迹 荧光定量PCR Cervical carcinoma Gene expression Real-time PCR Western-blot
  • 相关文献

参考文献12

  • 1马国中,王继生.蛋白质组学的临床实验与应用[J].中国实用医药,2008,3(30):201-203. 被引量:2
  • 2Wu G,Guo Z,Chang X,et al .LOXL1 and LOXL4 are epigeneticaUy silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer[J].Cancer Res,2007,67(9):4123-4129.
  • 3Li W, Liu G,Chou IN,et al.Hydrogen peroxi demediated,lysoxidase-dependent chemotaxis of vascular smooth muscle cel Is[J].J CellBi Chem,2000,78(4):550-557.
  • 4Sebban S,Golan-Gerstl R,Karni R. Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer[J]. Clin Exp Metastasis,2013,30(1):103-117.
  • 5Kim MS,Kim SS,Jung ST, et al.Expression and purification of enzymatically active forms of the human lysyl oxidase-like protein 4[J].J Biol Chem,2003,278(52):52071-52074.
  • 6Siddikuzzaman,Grace VM, Guruvayoorappan C. Lysyloxidase:a poteitial target for cancer therapy[J]. Inflammopharmacology,2011,19(3): 117-129.
  • 7Lin CY, Anders J, Johnson M,et al.Molecular cloning of cDNA for matriptase,a matrix-degrading serine protease with trypsin-like activity[J].J Biol Chem,1999,274(26):18231-18236.
  • 8List K,Bugge TH,Szabo R. Matriptase:potent proteolysis on the cell surface[J].Mol Med,2006,12(1/3):1-7.
  • 9Lee JW,Yong Song S,Choi JJ,etal.Increased expression of matriptase is associated with histopathologic grades ofcervicalneoplasia[J].Hum Pathol,2005,36(6):626-633.
  • 10Uhland K.Matriptase and its putative role in cancer[J].Cell Mol Life Sci,2006,63(24):2968-2978.

二级参考文献15

  • 1[1]Engwegen J.Y,Gast M.C,Schellens J.H,et al.Clinical proteomics:searching for better tumour markers with SELDITOFmass spectrometry.Trends Pharmacol.Sci,2006,27:251-259.
  • 2[2]Petricoin E.F,Ornstein D.K,Liotta L.A.Clinical proteomics:Applications for prostate cancer biomarker discovery and detection.Urol.Oncol,2004,22:322-328.
  • 3[3]Banks R.E,Dunn M.J,Hochstrasser D.F,et al.Proteomics:new perspectives,new biomedical opportunities.Lancet,2000,356:1749-1756.
  • 4[4]Stein L.D.Human genome:end of the beginning.Nature,2004,431,:915-916.
  • 5[5]Schnitt S.J.Traditional and newer pathologic factors.J.Natl.Cancer Inst.Monogr,2001,30:22-26.
  • 6[6]Donegan W.L.Tumor-related prognostic factors for breast cancer.CA Cancer J.Clin,1997,47:28-51.
  • 7[7]Alaiya A,Al-Mohanna M,Linder S.Clinical cancer proteomics:promises and pitfalls.J.Proteome Res,2005,4:1213-1222.
  • 8[8]Ariazi EA,Ariazi JL,Cordera F,et al..Estrogen receptors as therapeutic targets in breast cancer.Curr.Top.Med Chem,2006,6:195-216.
  • 9[9]Cai Z,Chiu J.F,He Q.Y.Application of proteomics in the study of tumor metastasis.Genomics Proteomics Bioinformatics,2004,2:152-166.
  • 10[10]Hoehn G.T,Suffredini A.F.Proteomics.Crit.Care Med,2005,33(suppl.):444-448.

共引文献1

同被引文献4

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部